Company profile
LEO Pharma
Privately held: no public share price
Assets
(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Vitamin D receptor + Glucocorticoid receptorSmall molecule | Psoriasis | |
tralokinumab(Adbry) | Approved | IL-13Monoclonal antibody | Atopic Dermatitis |
| Phase 2 | IL-22 receptor subunit alpha-1 (IL-22RA1)Monoclonal antibody | Atopic Dermatitis |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.